세계의 심혈관 임상시험 시장 규모 조사 및 예측 : 단계별, 시험 디자인별, 적응증별, 지역별 분석(2022-2029년)

Global Cardiovascular Clinical Trials Market is valued at approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Clinical trials are medical research studies designed to assess novel approaches to disease prevention, diagnosis, and treatment. Clinical trials are used by researchers to evaluate the safety and efficacy of new treatments for patients. Clinical trials in the field of cardiovascular medicine particularly examine novel therapies for heart problems. Throughout the course of the projection period, it is predicted that the global market for cardiovascular clinical trials would expand significantly. The rising prevalence of cardiovascular disorders such as stroke, heart failure, and coronary artery diseases is one of the main reasons propelling the market's expansion. Also, growing government and industry investment as well as increased consumer demand for phase III trial cost reductions are both driving the market's expansion. Moreover, the rising high government support, growing initiatives by the key market players is creating a lucrative growth opportunity for the market over the forecast period 2022-2029.

For instance, cardiovascular disorders continue to be the major cause of death worldwide, according to a WHO report from 2021. Estimates indicate that 17.9 million individuals died from CVDs in 2019, with the bulk of these deaths occurring in low- and middle-income nations. Phase III clinical studies typically cost USD 22.8 million or more. Moreover, Phase III calls for a larger patient population and frequently a longer course of treatment. As of January 2023, there was about 830 cardiovascular phase III clinical studies listed on clinicaltrials.gov, according to clinicaltrials.gov. However, the high cost of Cardiovascular Clinical Trials stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Cardiovascular Clinical Trials Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. Due to factors such as increased R&D spending and rising cardiovascular disease prevalence, North America is predicted to have the largest market share over the projection period. For instance, from 2001 to 2025, many registered clinical trials and research dates originated in the United States. Clinicaltrials.gov estimates that 4,058 cardiovascular clinical trials will be conducted in the United States in 2022. Along with this, Asia-Pacific is growing with the fastest CARG over the forecast period due to the rising number of geriatric population and growing prevalence of cardiovascular diseases.

Major market players included in this report are:

• Medpace
• IQVIA Inc
• ICON Plc
• Charles River Laboratories Inc.
• Wuxi App Tec
• Laboratory Corporation of America Holdings
• PAREXEL International Corporation
• Eli Lilly and Company
• Pharmaceutical Product Development, LLC
• Pfizer Inc.

Recent Developments in the Market:

• In Aug 2021, The U.S. Food and Drug Administration (FDA) approved an expanded label for Eli Lilly and Company's rapid-acting Cardiovascular Clinical Trials, Lyumjev (Cardiovascular Clinical Trials lispro-AABC injection) 100 units/mL indicated to improve glycemic control in adults with Indication 1 and Indication 2 diabetes, to include administration via continuous subcutaneous Cardiovascular Clinical Trials infusion (CSII) with a Cardiovascular Clinical Trials pump.
• In July 2021, Semglee, a first-of-its-kind Cardiovascular Clinical Trials Phase made by India's Biocon, gets United States approval. Semglee, manufactured by Biocon Biologics, a Bengaluru-based pharmaceutical company, is both interchangeable with and biosimilar to Lantus, a long-acting Cardiovascular Clinical Trials Phase already approved in the United States.

Global Cardiovascular Clinical Trials Market Report Scope:

• Historical Data: 2019-2020-2021

• Base Year for Estimation: 2021

• Forecast period: 2022-2029

• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

• Segments Covered: Phase, Study Design, Indication, Region

• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Phase offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

By Study Design:

• Interventional
• Observational
• Expanded Access

By Indication:

• Acute Coronary Syndrome
• Coronary Artery Disease
• Ischemic Heart Disease
• Pulmonary Arterial Hypertension
• Stroke/Cerebrovascular Disease
• Cardiac Arrhythmias
• Heart Failure
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
  • 1.2.1. Cardiovascular Clinical Trials Market, by Region, 2019-2029 (USD Billion)
  • 1.2.2. Cardiovascular Clinical Trials Market, by Phase, 2019-2029 (USD Billion)
  • 1.2.3. Cardiovascular Clinical Trials Market, by Study Design, 2019-2029 (USD Billion)
  • 1.2.4. Cardiovascular Clinical Trials Market, by Indication, 2019-2029 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Cardiovascular Clinical Trials Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Cardiovascular Clinical Trials Market Dynamics

• 3.1. Cardiovascular Clinical Trials Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rising prevalence of cardiovascular disorders
    • 3.1.1.2. Growing Geriatric Population
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Cardiovascular Clinical Trials
  • 3.1.3. Market Opportunities
    • 3.1.3.1. High government support
    • 3.1.3.2. Rising inititiaves by the key market players

Chapter 4. Global Cardiovascular Clinical Trials Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Investment Adoption Model
• 4.5. Analyst Recommendation & Conclusion
• 4.6. Top investment opportunity
• 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Cardiovascular Clinical Trials Market, by Phase

• 6.1. Market Snapshot
• 6.2. Global Cardiovascular Clinical Trials Market by Phase, Performance - Potential Analysis
• 6.3. Global Cardiovascular Clinical Trials Market Estimates & Forecasts by Phase 2019-2029 (USD Billion)
• 6.4. Cardiovascular Clinical Trials Market, Sub Segment Analysis
  • 6.4.1. Phase I
  • 6.4.2. Phase II
  • 6.4.3. Phase III
  • 6.4.4. Phase IV

Chapter 7. Global Cardiovascular Clinical Trials Market, by Study Design

• 7.1. Market Snapshot
• 7.2. Global Cardiovascular Clinical Trials Market by Study Design, Performance - Potential Analysis
• 7.3. Global Cardiovascular Clinical Trials Market Estimates & Forecasts by Study Design 2019-2029 (USD Billion)
• 7.4. Cardiovascular Clinical Trials Market, Sub Segment Analysis
  • 7.4.1. Interventional
  • 7.4.2. Observational
  • 7.4.3. Expanded Access

Chapter 8. Global Cardiovascular Clinical Trials Market, by Indication

• 8.1. Market Snapshot
• 8.2. Global Cardiovascular Clinical Trials Market by Indication, Performance - Potential Analysis
• 8.3. Global Cardiovascular Clinical Trials Market Estimates & Forecasts by Indication 2019-2029 (USD Billion)
• 8.4. Cardiovascular Clinical Trials Market, Sub Segment Analysis
  • 8.4.1. Acute Coronary Syndrome
  • 8.4.2. Coronary Artery Disease
  • 8.4.3. Ischemic Heart Disease
  • 8.4.4. Pulmonary Arterial Hypertension
  • 8.4.5. Stroke/Cerebrovascular Disease
  • 8.4.6. Cardiac Arrhythmias
  • 8.4.7. Heart Failure
  • 8.4.8. Others

Chapter 9. Global Cardiovascular Clinical Trials Market, Regional Analysis

• 9.1. Cardiovascular Clinical Trials Market, Regional Market Snapshot
• 9.2. North America Cardiovascular Clinical Trials Market
  • 9.2.1. U.S. Cardiovascular Clinical Trials Market
    • 9.2.1.1. Phase breakdown estimates & forecasts, 2019-2029
    • 9.2.1.2. Study Design breakdown estimates & forecasts, 2019-2029
    • 9.2.1.3. Indication breakdown estimates & forecasts, 2019-2029
  • 9.2.2. Canada Cardiovascular Clinical Trials Market
• 9.3. Europe Cardiovascular Clinical Trials Market Snapshot
  • 9.3.1. U.K. Cardiovascular Clinical Trials Market
  • 9.3.2. Germany Cardiovascular Clinical Trials Market
  • 9.3.3. France Cardiovascular Clinical Trials Market
  • 9.3.4. Spain Cardiovascular Clinical Trials Market
  • 9.3.5. Italy Cardiovascular Clinical Trials Market
  • 9.3.6. Rest of Europe Cardiovascular Clinical Trials Market
• 9.4. Asia-Pacific Cardiovascular Clinical Trials Market Snapshot
  • 9.4.1. China Cardiovascular Clinical Trials Market
  • 9.4.2. India Cardiovascular Clinical Trials Market
  • 9.4.3. Japan Cardiovascular Clinical Trials Market
  • 9.4.4. Australia Cardiovascular Clinical Trials Market
  • 9.4.5. South Korea Cardiovascular Clinical Trials Market
  • 9.4.6. Rest of Asia Pacific Cardiovascular Clinical Trials Market
• 9.5. Latin America Cardiovascular Clinical Trials Market Snapshot
  • 9.5.1. Brazil Cardiovascular Clinical Trials Market
  • 9.5.2. Mexico Cardiovascular Clinical Trials Market
• 9.6. Rest of The World Cardiovascular Clinical Trials Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. Medpace
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. IQVIA Inc.
  • 10.2.3. ICON Plc
  • 10.2.4. Charles River Laboratories Inc.
  • 10.2.5. Wuxi App Tec
  • 10.2.6. Laboratory Corporation of America Holdings
  • 10.2.7. PAREXEL International Corporation
  • 10.2.8. Eli Lilly and Company
  • 10.2.9. Pharmaceutical Product Development, LLC
  • 10.2.10. Pfizer Inc.

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption